Generation and characterization of a control and patient-derived human iPSC line containing the Hermansky Pudlak type 2 (HPS2) associated heterozygous compound mutation in AP3B1
DOI: 10.1016/j.scr.2021.102444
Authors: Cathelijn E.M. Aarts; Ellie Karampini; Tatjana Wüst; Steven Webbers; Eszter Varga; Judy Geissler; Jan Voorberg; Marieke von Lindern; Ruben Bierings; Emile van den Akker; Taco W. Kuijpers
Step 1: iPSC/ESC maintainance
day 0 ~ 2
culture “adherent” human PSC in “E8” for “2” days. For ECM, use “Matrigel” at “N/A” “N/A”. Medium should contain factors shown in the following table, and should be changed once in “2” days.
| concentration | unit | |
|---|---|---|
| Revitacell | — | — |
Ideally, “PSC” should express “SSEA4”, “POU5F1”, “SOX2”, “TRA-1-60”, “TRA-1-81”, “NANOG” at the end of culture.